Last updated: August 31, 2021
Sponsor: Ruijin Hospital
Overall Status: Active - Recruiting
Phase
2
Condition
Cardiac Ischemia
Blood Clots
Myocardial Ischemia
Treatment
N/AClinical Study ID
NCT04803864
SHDC2020CR2023B
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Acute STEMI (ST segment elevation myocardial infarction) diagnosed by ST elevation
- Coronary angiography within 12 hours of symptom onset, with TIMI flow grade 0 - 1 ofculprit vessel
- Primary PCI with TIMI flow grade 2 - 3 after successful intervention
- Capable and willing to provide informed consent and capable of completing study visits
Exclusion
Exclusion Criteria:
- Previous acute myocardial infarction history
- Cardiogenic Shock at admission
- Previously treated by roxadustat
- Contraindications of roxadustat treatment
- Contraindication of Cardiac MRI (e.g. eGFR < 30 ml/min, pacemaker, metal prosthesis,etc.)
Study Design
Total Participants: 158
Study Start date:
June 10, 2021
Estimated Completion Date:
August 31, 2023
Study Description
Connect with a study center
Ruijin Hospital
Shanghai, Shanghai 200025
ChinaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.